OS and PFS according to anthracycline (Anthra) and Anthra + etoposide (ETO) treatments. Kaplan-Meier analysis of OS and PFS in patients with ALK^– ALCL stratified according to use of ETO in combination with Anthra. (A) Five-year rates of OS in the ETO cohort vs no ETO cohort were 69% vs 44%, respectively. (B) Five-year rates of PFS in the ETO cohort vs the no ETO cohort were 50% vs 39%, respectively.